Kailera Therapeutics filed an S-1 for a proposed Nasdaq IPO on March 27-28, 2026, under symbol 'KLRA', to fund its obesity drug development pipeline12346.
The company, based in Waltham, Massachusetts and founded in 2024 with $400M funding, has four obesity candidates licensed from Jiangsu Hengrui Pharmaceuticals46.
An experimental oral obesity drug from Kailera and Hengrui showed up to 12.1% body weight loss after 26 weeks in a mid-stage China study4.
Lead underwriters include J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and William Blair14.
Kailera focuses on GLP-1 receptor agonists for obesity, amid surging demand and competition from Novo Nordisk and Eli Lilly46.
Sources:
1. https://www.investing.com/news/stock-market-news/kailera-therapeutics-files-for-proposed-nasdaq-ipo-432SI-4585879
2. https://fazen.markets/en/kailera-therapeutics-us-ipo-obesity-drugs
3. https://www.tradingview.com/news/reuters.com,2026:newsml_L4N40F1LY:0-kailera-therapeutics-files-for-us-ipo/
4. https://www.czarnikforsenate.com/world/9615/
6. https://nationaltoday.com/us/ma/waltham/news/2026/03/28/glp-1-developer-kailera-proteomics-firm-alamar-file-for-ipo/